Stavudine

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Stavudine is an ofm drug in the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1994. Its mechanism of action is classified as Nucleoside Reverse Transcriptase Inhibitors. DrugCentral lists 3 molecular targets, including pol, reverse transcriptas and gag-pol. Recorded indications include Human immunodeficiency virus infection.

• Approval status: ofm (first approved 1994 by the FDA).
• Drug class: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.
• Mechanism of action: Nucleoside Reverse Transcriptase Inhibitors.
• Molecular targets: pol, reverse transcriptas and gag-pol (3 listed in DrugCentral).
• Indications: Human immunodeficiency virus infection.
• ATC code: J05AF04 (Nucleoside and nucleotide reverse transcriptase inhibitors).
• Molecular formula: C10H12N2O4; molecular weight 224.22 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Human immunodeficiency virus infection

Off-label uses (1)

• Prevention of HIV Infection after Exposure

Contraindications (12)

• Acute pancreatitis
• Alcoholism
• Breastfeeding (mother)
• Chronic pancreatitis
• Diabetes mellitus
• Disease of liver
• Hyperglycemia
• Kidney disease
• Lactic acidosis
• Obesity
• Peripheral nerve disease
• Steatosis of liver

Mechanism & targets

• Mechanism of action (MoA): Nucleoside Reverse Transcriptase Inhibitors
• Established pharmacologic class: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Molecular targets (3)

Target	Gene	Action	Activity
Reverse transcriptase/RNaseH	pol	inhibitor	EC50 7.30
Reverse transcriptase	reverse transcriptas	unknown	IC50 7.22
Gag-Pol polyprotein	gag-pol	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1994-06-24	FDA	—	BRISTOL MYERS SQUIBB

ATC classification

ATC code	Therapeutic hierarchy
J05AF04	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleoside and nucleotide reverse transcriptase inhibitors
J05AR07	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
J05AR28	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Virologic failure	2198.0
Viral mutation identified	1374.5
Lipodystrophy acquired	1332.0
Drug resistance	1293.5
Mitochondrial toxicity	798.3
Pathogen resistance	795.6
Foetal exposure during pregnancy	619.0
Eyelid ptosis	515.1
Progressive external ophthalmoplegia	428.1
Treatment failure	355.8
Diplopia	337.5
Multiple-drug resistance	323.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Stavudine is on its molecule page.

• Molecular formula: C₁₀H₁₂N₂O₄
• Molecular weight: 224.22 g/mol
• CAS number: 3056-17-5
• InChIKey: XNKLLVCARDGLGL-JGVFFNPUSA-N
• PubChem CID: 18283

CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Stavudine used for?

DrugCentral lists the following indications for Stavudine: Human immunodeficiency virus infection.

How does Stavudine work?

Stavudine is classified as Nucleoside Reverse Transcriptase Inhibitors; its molecular targets in DrugCentral include pol (inhibitor), reverse transcriptas and gag-pol.

When was Stavudine first approved?

Stavudine was first approved by the FDA in 1994.

What drug class does Stavudine belong to?

Stavudine is in the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class.

What is the chemical formula of Stavudine?

Stavudine has the molecular formula C10H12N2O4 and a molecular weight of 224.22 g/mol.

Sources

• DrugCentral drug card 2478 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL991 — compound record and bioactivity
• PubChem CID 18283 — chemical identifiers
• DrugBank DB00649 — drug record
• FDA UNII BO9LE4QFZF — substance identity
• DailyMed: FDA labels for Stavudine — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.